Analyst Price Target is $21.25
▲ +80.24% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Artiva Biotherapeutics in the last 3 months. The average price target is $21.25, with a high forecast of $23.00 and a low forecast of $18.00. The average price target represents a 80.24% upside from the last price of $11.79.
Current Consensus is
Buy
The current consensus among 5 contributing investment analysts is to buy stock in Artiva Biotherapeutics.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Read More
